Jobsatcordacampus.jpg

Stay Notified Of Our Blog Updates

Announcing our $ 9.3 million Series A funding

Thomas Beuls | Funding | Press Release | UgenTec | 29/03/2018

We're excited to announce our series A funding round. Existing and new investors subscribed to the round for a total worth of $9,3 million (€7,5 million). The funds will be used to consolidate our leading position in clinical diagnostics, setting up a US office and expanding to new markets.

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Thomas Beuls | Press Release | Partnership | 23/01/2018

HERSTAL & HASSELT, BELGIUM – 23/01/18 | UgenTec, an innovative European medical device software company that develops artificially intelligent PCR interpretation software, announced today a partnership agreement with MDxHealth, a multinational healthcare company that uses molecular diagnostics to personalize urological cancer diagnosis and treatment.

UgenTec expands management team and appoints Steven Verhoeven as CEO

Thomas Beuls | Press Release | UgenTec | 19/12/2017

Hasselt, Belgium, December 19, 2017. | Steven Verhoeven, previously Agilent’s head of genomics software, will join UgenTec to take up the role of chief executive officer, the current role of founder Wouter Uten. Verhoeven will be responsible for continuing the exponential growth of UgenTec, exploring new markets & maintaining investor relations.

Fast Track Diagnostics and UgenTec announce new interpretation software for all FTD real-time PCR multiplex kits

Thomas Beuls | Press Release | Partnership | 5/12/2017

LUXEMBOURG, LUXEMBOURG & HASSELT, BELGIUM – 05/12/17 | Fast Track Diagnostics S.à.r.l., one of the leading global suppliers of syndromic real-time PCR multiplexing kits, has been partnering for several months with UgenTec NV, an innovative European medical device software company that develops artificially intelligent PCR interpretation software.

R-Biopharm AG & UgenTec partner to develop software for automated PCR analysis

Thomas Beuls | Press Release | Partnership | 21/09/2017

DARMSTADT, GERMANY and HASSELT, BELGIUM, September 21st, 2017 – R-Biopharm AG announced today it has entered into an agreement with UgenTec to collaborate on developing an interpretation software for R-Biopharm’s clinical PCR (Polymerase Chain Reaction) kits